DNA demethylating agent decitabine broadens the peripheral T cell receptor repertoire.

ABSTRACT:

Purpose

Decitabine, a promising epi-immunotherapeutic agent has shown clinical responses in solid tumor patients, while the anti-tumor mechanisms were unclear. We aimed to investigate the immunomodulatory effect of decitabine in peripheral T cells.

Experimental design

We applied next-generation sequencing to investigate the complementarity-determining region 3 (CDR3) of the TCRβ gene, the diversity of which acts as the prerequisite for the host immune system to recognize the universal foreign antigens. We collected the peripheral blood mononuclear cells (PBMCs) from 4 patients, at baseline and after 2 cycles of low-dose decitabine therapy.

Results

An increase of the unique productive sequences of the CDR3 of TCRβ was observed in all of the 4 patients after decitabine

SUBMITTER: Nie J 

PROVIDER: S-EPMC5122357 | biostudies-literature | 2016 Jun

REPOSITORIES: biostudies-literature